癌症治疗中必须管理不良事件（AEs）。我们先前开发了一份药物指导表（MGS），用于监测异基因造血干细胞移植（HSCT）预处理疗法后的AEs。然而，尚不清楚该表能否准确预测临床实践中的AEs的类型、发生时间和持续时间。在本研究中，我们评估了原始MGS在接受全身放疗（TBI）和环磷酰胺（CY）的患者中的临床效用。纳入了接受TBI/CY的58名患者。将实际监测到的AEs的类型、发生时间和持续时间与原始MGS中列出的进行比较。观察到了总共361种主观AE症状，全部都是预测性的，与MGS中列出的一致。然而，一些AEs的持续时间比预期要长。因此，对于所有AEs的预测准确率为67.0%。准确率最低的是食欲不振（6.7%），其次是腹泻（42.6%）和恶心/呕吐（55.6%）。急性移植物抗宿主病（GVHD）最可能导致AEs的延长。随后，根据急性GVHD的可能发生，对原始MGS进行了修订。当监测接受TBI/CY预处理方案进行HSCT的患者的AEs时，应考虑急性GVHD相关AEs的参与。在这方面，经过修改的现有MGS对于快速和准确监测AEs尤其有用。版权所有©2023International Institute of Anticancer Research（Dr. George J. Delinasios）保留所有权利。

Adverse events (AEs) must be managed during cancer therapy. We had previously developed a medication guidance sheet (MGS) to monitor AEs after conditioning therapy with allogeneic hematopoietic stem cell transplantation (HSCT). However, it remains unclear whether this sheet can accurately predict the type, onset, and duration of AEs in clinical practice. In this study, we evaluated the clinical utility of the original MGS in patients receiving total body irradiation (TBI) and cyclophosphamide (CY).Fifty-eight patients who underwent TBI/CY were included. The types, onsets, and durations of AEs observed during real monitoring were compared with those listed in the original MGS.A total of 361 subjective AE symptoms were observed, all of which were predictive, as listed in the MGS. However, the durations of several AEs were longer than expected. Thus, the prediction accuracy for all AEs was 67.0%. The accuracy rate was the lowest for anorexia (6.7%), followed by diarrhea (42.6%), and nausea/vomiting (55.6%). Acute graft versus host disease (GVHD) most likely caused the prolongation of AEs. Subsequently, the original MGS was revised to account for the possible occurrence of acute GVHD.When monitoring AEs in patients receiving a TBI/CY conditioning regimen for HSCT, the involvement of acute GVHD-associated AEs should be considered. In this respect, the present modified MGS is particularly useful for rapid and accurate monitoring of AEs.Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.